Eton Pharmaceuticals (ETON) Debt to Equity (2020 - 2025)

Eton Pharmaceuticals has disclosed Debt to Equity across 6 years of filings, most recently posting $1.17 for Q4 2025.

• Debt to Equity for Q4 2025 came in at $1.17, down 4.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.17 (down 4.26% YoY), and the FY2025 annual result was $1.17, down 4.26% from the prior year.
• Debt to Equity came in at $1.17 for Q4 2025 at Eton Pharmaceuticals, down from $1.31 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.31 in Q3 2025 to a low of $0.02 in Q1 2021.
• The 5-year median for Debt to Equity is $0.11 (2023), against an average of $0.38.
• Across the five-year window, Debt to Equity slipped 23.9% in 2022 and jumped 408.72% in 2025, its largest moves.
• Eton Pharmaceuticals' Debt to Equity stood at $0.08 in 2021, then declined by 1.79% to $0.08 in 2022, then jumped by 340.08% to $0.35 in 2023, then soared by 251.07% to $1.22 in 2024, then decreased by 4.26% to $1.17 in 2025.
• The last three Debt to Equity figures came in at $1.17 (Q4 2025), $1.31 (Q3 2025), and $1.26 (Q2 2025), per Business Quant data.